Literature DB >> 21952928

The phosphatidyl inositol 3 kinase-glycogen synthase kinase 3β pathway mediates bilobalide-induced reduction in amyloid β-peptide.

Chun Shi1, Dong-dan Zheng, Feng-ming Wu, Jun Liu, Jie Xu.   

Abstract

Bilobalide (BB), a sesquiterpenoid extract of Ginkgo biloba leaves, has been demonstrated to have neuroprotective effects. The neuroprotective mechanisms were suggested to be associated with modulation of intracellular signaling cascades such as the phosphatidyl inositol 3-kinase (PI3K) pathway. Since some members of intracellular signalling pathways such as PI3K have been demonstrated to be involved in amyloid precursor protein (APP) processing, the present study investigated whether BB has an influence on the β-secretase-mediated APP cleavage via PI3K-dependent pathway. Using HT22 cells and SAMP8 mice (a senescence-accelerated strain of mice), this study showed that BB treatment reduced generation of two β-secretase cleavage products of APP, the amyloid β-peptide (Aβ) and soluble APPβ (sAPPβ), via PI3K-dependent pathway. Additionally, glycogen synthase kinase 3β (GSK3β) signaling might be involved in BB-induced Aβ reduction as a downstream target of the activated PI3K pathway. BB showed no significant effects on β-site APP cleaving enzyme 1 (BACE-1) or γ-secretase but inhibited the β-secretase activity of another protease cathepsin B, suggesting that BB-induced Aβ reduction was probably mediated through modulation of cathepsin B rather than BACE-1. Similarly, inhibition of GSK3β did not affect BACE-1 activity but decreased cathepsin B activity, suggesting that the PI3K-GSK3β pathway was probably involved in BB-induced Aβ reduction. Increasing evidence suggests that decreasing Aβ production in the brain via modulation of APP metabolism should be beneficial for the prevention and treatment of Alzheimer's disease (AD). BB may offer such an approach to combat AD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21952928     DOI: 10.1007/s11064-011-0612-1

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  28 in total

1.  Resveratrol blocks interleukin-18-EMMPRIN cross-regulation and smooth muscle cell migration.

Authors:  Balachandar Venkatesan; Anthony J Valente; Venkatapuram Seenu Reddy; Deborah A Siwik; Bysani Chandrasekar
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-06-26       Impact factor: 4.733

2.  The cysteine protease inhibitor, E64d, reduces brain amyloid-β and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, β-secretase activity.

Authors:  Gregory Hook; Vivian Hook; Mark Kindy
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

3.  The PI3K-Akt pathway regulates calpain 6 expression, proliferation, and apoptosis.

Authors:  Yonglei Liu; Chuanzhong Mei; Lidong Sun; Xin Li; Mingzhu Liu; Liying Wang; Zengxia Li; Peng Yin; Chao Zhao; Yinghong Shi; Shuangjian Qiu; Jia Fan; Xiliang Zha
Journal:  Cell Signal       Date:  2011-01-19       Impact factor: 4.315

4.  Bilobalide protects mitochondrial function in ovariectomized rats by up-regulation of mRNA and protein expression of cytochrome c oxidase subunit I.

Authors:  Chun Shi; Juntao Zou; Guoying Li; Zhenying Ge; Zhibin Yao; Jie Xu
Journal:  J Mol Neurosci       Date:  2010-05-20       Impact factor: 3.444

Review 5.  Potential therapeutic targets of huperzine A for Alzheimer's disease and vascular dementia.

Authors:  Hai Yan Zhang; Chun Yan Zheng; Han Yan; Zhi Fei Wang; Li Li Tang; Xin Gao; Xi Can Tang
Journal:  Chem Biol Interact       Date:  2008-05-13       Impact factor: 5.192

6.  Restoration of impaired phosphorylation of cyclic AMP response element-binding protein (CREB) by EGb 761 and its constituents in Abeta-expressing neuroblastoma cells.

Authors:  Yanan Xu; Changhai Cui; Cheuk Pang; Yves Christen; Yuan Luo
Journal:  Eur J Neurosci       Date:  2007-11       Impact factor: 3.386

7.  Staurosporine restores signaling and inhibits interleukin-8-induced chemotactic desensitization.

Authors:  J A Johnston; D K Ferris; J M Wang; D L Longo; J J Oppenheim; D J Kelvin
Journal:  Eur J Immunol       Date:  1994-10       Impact factor: 5.532

8.  Liquid chromatography/atmospheric pressure chemical ionization ion trap mass spectrometry of bilobalide in plasma and brain of rats after oral administration of its phospholipidic complex.

Authors:  Rossana Rossi; Fabrizio Basilico; Giuseppe Rossoni; Antonella Riva; Paolo Morazzoni; Pier Luigi Mauri
Journal:  J Pharm Biomed Anal       Date:  2009-05-03       Impact factor: 3.935

Review 9.  BACE1: the beta-secretase enzyme in Alzheimer's disease.

Authors:  Robert Vassar
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

10.  A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo.

Authors:  L Serenó; M Coma; M Rodríguez; P Sánchez-Ferrer; M B Sánchez; I Gich; J M Agulló; M Pérez; J Avila; C Guardia-Laguarta; J Clarimón; A Lleó; T Gómez-Isla
Journal:  Neurobiol Dis       Date:  2009-06-10       Impact factor: 5.996

View more
  7 in total

1.  Tanshinone IIA promotes non-amyloidogenic processing of amyloid precursor protein in platelets via estrogen receptor signaling to phosphatidylinositol 3-kinase/Akt.

Authors:  Chun Shi; Xiaoming Zhu; Jisheng Wang; Dahong Long
Journal:  Biomed Rep       Date:  2014-03-24

Review 2.  Current Progress on Neuroprotection Induced by Artemisia, Ginseng, Astragalus, and Ginkgo Traditional Chinese Medicines for the Therapy of Alzheimer's Disease.

Authors:  Qin Li; Limor Rubin; Marta Silva; Shuai Li; Chao Yang; Philip Lazarovici; Wenhua Zheng
Journal:  Oxid Med Cell Longev       Date:  2022-06-14       Impact factor: 7.310

3.  Estrogen Receptors Are Involved in the Neuroprotective Effect of Silibinin in Aβ1-42-Treated Rats.

Authors:  Xiaoyu Song; Bo Liu; Lingyu Cui; Biao Zhou; Lu Liu; Weiwei Liu; Guodong Yao; Mingyu Xia; Toshihiko Hayashi; Shunji Hattori; Yuko Ushiki-Kaku; Shin-Ichi Tashiro; Takashi Ikejima
Journal:  Neurochem Res       Date:  2018-02-03       Impact factor: 3.996

4.  Brain pyroglutamate amyloid-β is produced by cathepsin B and is reduced by the cysteine protease inhibitor E64d, representing a potential Alzheimer's disease therapeutic.

Authors:  Gregory Hook; Jin Yu; Thomas Toneff; Mark Kindy; Vivian Hook
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

5.  Compensating for synaptic loss in Alzheimer's disease.

Authors:  Kamal Abuhassan; Damien Coyle; Ammar Belatreche; Liam Maguire
Journal:  J Comput Neurosci       Date:  2013-06-02       Impact factor: 1.621

6.  Natural products as promising drug candidates for the treatment of Alzheimer's disease: molecular mechanism aspect.

Authors:  Niloufar Ansari; Fariba Khodagholi
Journal:  Curr Neuropharmacol       Date:  2013-07       Impact factor: 7.363

7.  Zerumbone ameliorates behavioral impairments and neuropathology in transgenic APP/PS1 mice by suppressing MAPK signaling.

Authors:  Lei Li; Xiang-Hui Wu; Xiao-Jing Zhao; Lu Xu; Cai-Long Pan; Zhi-Yuan Zhang
Journal:  J Neuroinflammation       Date:  2020-02-17       Impact factor: 8.322

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.